Jennifer Marlowe - Dec 2, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
CSO
Signature
/s/ David Tyronne Howton as attorney-in-fact for Jennifer Marlowe
Stock symbol
SLDB
Transactions as of
Dec 2, 2023
Transactions value $
-$13,525
Form type
4
Date filed
12/5/2023, 02:30 PM
Previous filing
Dec 5, 2022
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +11.9K 11.9K Dec 2, 2023 Direct F1
transaction SLDB Common Stock Sale -$13.5K -4.89K -41.13% $2.77 7K Dec 4, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -11.9K -25% $0.00 35.7K Dec 2, 2023 Common Stock 11.9K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2 This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F3 The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.